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Abstract
Background: Host genetic factors may play a role in the occurrence and progress of SARS-Cov
infection. This study was to investigate the relationship between tumor necrosis factor (TNF)-α
gene polymorphisms with the occurrence of SARS-CoV infection and its role in prognosis of
patients with lung interstitial fibrosis and femoral head osteonecrosis.
Methods: The association between genetic polymorphisms of TNF-α gene and susceptibility to
severe acute respiratory syndromes (SARS) was conducted in a hospital-based case-control study
including 75 SARS patients, 41 health care workers and 92 healthy controls. Relationships of TNF-
α gene polymorphisms with interstitial lung fibrosis and femoral head osteonecrosis were carried
out in two case-case studies in discharged SARS patients. PCR sequencing based typing (PCR-SBT)
method was used to determine the polymorphisms of TNF-α gene in locus of the promoter region
and univariate logistic analysis was conducted in analyzing the collected data.
Results: Compared to TT genotype, the CT genotype at the -204 locus was found associated with
a protective effect on SARS with OR(95%CI) of 0.95(0.90–0.99). Also, TT genotype, CT and CC
were found associated with a risk effect on femoral head necrosis with ORs(95%CI) of
5.33(1.39–20.45) and 5.67(2.74–11.71), respectively and the glucocorticoid adjusted OR of CT was
5.25(95%CI 1.18–23.46) and the combined (CT and CC) genotype OR was 6.0 (95%CI 1.60–22.55)
at -1031 site of TNF-α gene. At the same time, the -863 AC genotype was manifested as another
risk effect associated with femoral head necrosis with OR(95%CI) of 6.42(1.53–26.88) and the
adjusted OR was 8.40(95%CI 1.76–40.02) in cured SARS patients compared to CC genotype.
Conclusion: SNPs of TNF-α gene of promoter region may not associate with SARS-CoV infection.
And these SNPs may not affect interstitial lung fibrosis in cured SARS patients. However, the -
1031CT/CC and -863 AC genotypes may be risk factors of femoral head necrosis in discharged
SARS patients.
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Background
TNF, the gene encoding tumour necrosis factor (TNF),
resides in the central part (class III region) of the major
histocompatibility complex (MHC) surrounded by a large
number of other immunological genes [1]. Because of the
special locus of this gene, it can be deduced that this gene
may associate with many diseases, and this hypothesis
was confirmed by many research results [2,3]. TNF-α is a
key mediator of the inflammatory response and is critical
for host defense against a wide variety of pathogenic
microbes. However, the over-expression of this cytokine
may lead to badness in disease recovery. The dual role of
TNF, acting as an agent of both innate immunity and
inflammatory pathology, poses a considerable challenge
for gene regulation [2], and this regulation mainly located
on promoter region of this gene. The capacity for cytokine
production in an individual has a major genetic compo-
nent, and striking differences existed among individuals
in terms of their ability to produce cytokines. Several bial-
lelic polymorphisms had been described within the TNF-
α gene, including seven in the promoter region at posi-
tions -1031T→C, -863C→A, -857C→T, -376G→A, -
308G→A, -238G→A and -163G→A base pairs from the
transcription start site [4,5]. Moreover, a number of stud-
ies had shown that the TNF-α promoter polymorphism
had a significant effect on its transcriptional activity [6,7].
Severe acute respiratory syndrome (SARS) is a newly
described human infectious disease caused by a novel
coronavirus-SARS-CoV. SARS-CoV infection is important
because of its high infectivity and unpredictable clinical
course, which is characterized by a high mortality rate [8].
Till now, many researchers had reported that susceptibili-
ties to infection SARS-CoV may associated with HLA,
MXA, OAS-1 and CLEC4M gene polymorphisms [9-13],
yet these results were variable in different populations.
For example, Ng reported that SARS-CoV infection was
associated with HLA-B*0703  and  HLA-DRB1*0301  in
HongKong population [9], however, Lin's results showed
that HLA-B*4601 and HLA-B*5401 were closely related to
SARS-CoV infection [10]. Chan reported that CLEC4M
was attributed to SARS-CoV infection [13], but Zhi's
results failed to support this conclusion.7 These differ-
ences may be attributed to the study population used in
each report, also the complex mechanism infection to
SARS-CoV should be considered as another factor of these
differences. In order to explore more host factors influenc-
ing the occurrence of SARS-CoV infection, we studied the
polymorphisms of TNF-α gene at the promoter region,
which had been ascribed to polymorphisms within the
regulatory regions or signal sequences of cytokine genes
[14].
After discharging from hospital, interstitial lung fibrosis
was observed in SARS patients. Clinical data showed that
the prevalence rate of this change was 21%(42/200) in
cured SARS patients nine months from the discharge [15].
TNF-α was one of the earliest cytokines implicated in the
pathogenesis of lung fibrosis diseases and, together with
IL-1, has been found to over-expressed in regenerated type
II pneumocytes in human lung, thus enhanced fibroblast
proliferation [16]TNF-α polymorphisms have been dis-
covered significantly associated with increased risk of
developing pulmonary fibrosis [17,18]. Given that genetic
variation may potentially alter inflammation and fibrosis
in the lung, the aim of this case-case control study was to
examine the TNF-α polymorphisms with interstitial lung
fibrosis in SARS patients.
In spite of interstitial lung fibrosis in cured SARS patients,
another sequela – femoral head necrosis was also
observed in this population and the prevalence rate was
22.07%(49/221) and 23.1%(18/78) in Tianjin and Bei-
jing patients respectively [15,19]. The cause of this disease
was still unknown and there were arguments about it. For
example, some author considered SARS-CoV as the cause
of femoral head necrosis, yet other authors disagreed with
this view [20,21]. Previous studies showed that femoral
head necrosis may caused by hormone usage [20], yet our
data failed to agree with this point. So, it need further
study to explore the cause of this sequela and TNF-α pol-
ymorphisms were considered first in this report.
In this paper, we aimed to study whether polymorphisms
in TNF-α promoter region were associated with SARS-CoV
infection, development, and progression of interstitial
lung fibrosis and femoral head necrosis in cure SARS
patients.
Methods
Subjects
This study was reviewed and approved by ethics commit-
tees in the Medical College of CPAFP. The study popula-
tion comprised 75 SARS patients in Pingjin hospital,
Tianjin, China, 41 health care workers of the same hospi-
tal, who had come into contact with SARS patients but
had not developed into SARS, and 66 individuals having
no contact history with SARS patients. Among 75 SARS
patients, 55 could be classified into severe and light SARS
according to their clinical condition history during the
hospitalized period and this population also had the his-
tory of hormone therapy by reviewing the clinical treat-
ment. Anti-SARS-CoV antibodies of the serum samples
were tested by SARS ELISA kits (Huada Diagnostics Ltd,
Beijing, China).
Considered that the progression of interstitial lung fibro-
sis or femoral head necrosis may be affected by hormone
therapy, hormone using dosage, method and lasting
period were considered in this study when analyzing theBMC Infectious Diseases 2008, 8:27 http://www.biomedcentral.com/1471-2334/8/27
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associations between gene polymorphisms with disease.
Three kinds of hormone were used in SARS patients
including methylprednisolone, deltadehydrocortisone
and dexamethasone. In order to simplify analyzing, delta-
dehydrocortisone and dexamethasone dosage were calcu-
lated into methylprednisolone using the following
equation: 4 mg methylprednisolone = 5 mg deltadehydro-
cortisone = 0.75 mg dexamethasone. Lash therapy means
more than 320 mg methylprednisolone were used in a
single day.
Cured SARS patients with interstitial lung fibrosis were
diagnosed by respiratory experts according to CT results
following the standard proposal for therapy and diagnosis
of SARS patients issued by Chinese Ministry of Health in
2004 [22]. Interstitial lung fibrosis of SARS patients man-
ifested as irregular patch and strip shadow or high density
strip shadow and honeycomb interstitial lung fibrosis,
these changes could combine with the bronchiectasis.
Femoral head necrosis was diagnosed using magnetic res-
onance imaging (MRI). An MRI scan of a normal femoral
head would show uniformly high signal intensity on T1-
and T2-weighting throughout the femoral head. Agree
with one of the following image could be diagnosed as
femoral head necrosis in SARS patients: Abnormal signal
with clear margin in cartilage of femoral head, or double
thread image, or fracture or joint dent under cartilage, or
T1WI low signal, T2WI and STIR high signal of the mar-
row cavity edema with blur edge [22].
Genomic DNA extraction and polymerase chain reaction
Leucocytes were isolated within 12 h of blood collection
using Percoll reagent. Then genomic DNA was extracted
using cell DNA extraction kit (Tiangen BioTec Co, Beijing,
China, patch number: 2004-08-13) according to the man-
ufacturer's instructions. Primers were designed according
to Gewaltig [23]. Standard 50-μL polymerase chain reac-
tions (PCRs) contained 5 μl(6.7 μM) forward primer 5'-
GATGGACTCACCAGGTGAG-3', 5 μl(6.7  μM) reverse
primer 5'-CTCATGGTGTCCTTTCCAGG-3', 5 μl buffer
[150 mm (NH4)2SO4, 500 mM Tris-Cl(pH = 8.8), 500 μM
EDTA-Na2,15 mM MgCl2,100 mM β-Mercaptoethanol],
0.5  μL DNA polymerase (Tiangen BioTec Co, Beijing,
China), 3 μl DNA template. Amplification was carried out
in a thermal cycler TC312 (Techne, Duxford Cambridge,
UK) with cycle parameters of 5 min at 94°C (initial dena-
turation), 35 rounds of 94°C 30 s, 60°C 100 s and 72°C
150 s, and a final extension for 5 min at 72°C. The reac-
tions were carried out in molecular BioProducts 200 μL
capped tubes, as these gave optimal heat transfer in the
thermal cycler.
Sequencing of TNF-α gene fragments
The TNF-α gene 1279 bp fragments in this paper were
sequenced in double directions with forward primer 5'-
GATGGACTCACCAGGTGAG-3' and reverse primer 5'-
CTCATGGTGTCCTTTCCAGG-3' and Invitrogen company
(Invitrogen Co, Shanghai, China) using ABI 373 thermal
cycler carried out this job. The homozygote genotype of
each SNP site manifested as a single peak, yet the hetero-
zygote with an ambiguous nucleotide position of a dou-
ble color peak in the Big Dye chemistry pictures.
According to reading the sequence graphs, the genotype
was determined.
Statistics
The differences in values between two groups were evalu-
ated by Chi analysis for frequencies or student t test for
quantitative index and binary logistic regression was done
using SPSS 11.5 software (SPSS Inc, Chicago, Illinois,
USA).
Results
Demographic characteristics of the populations
A total of 75 SARS patients, 41 health care workers and 66
individuals were included in this study. All the popula-
tions were Chinese Han ethnic. The mean age was 35.0
years for SARS, 35.7 for health care workers and 30.1 for
individual controls (SARS Vs HCW, P > 0.05; SARS Vs
individual control, P > 0.05). The proportion of male was
30.6% in SARS, 26.8% in health care workers and 69.5%
in individual controls (SARS Vs HCW, P > 0.05; SARS Vs
individual control, P < 0.05). The sera positive rate anti-
SARS-CoV antibody was 100.0% in SARS, significantly
higher than that of health care workers and individual
controls (SARS Vs HCW, P < 0.05; SARS Vs individual con-
trol, P < 0.05) (Table 1).
TNF-α polymorphisms and SARS-Cov infection
TNF-α genotype frequencies were variable in SARS, health
care workers and individual controls. There were no dif-
ferences of TNF-α  genotype distribution at the -
1031(T→C), -863(C→A), -572(A→C), -308(G→A) and -
Table 1: Demographic characteristics of the populations
Characteristics SARS (N = 75) Health care workers (N = 41) Control (N = 92)
Age(years), mean [range] 35.0 [16-78] 35.7 [25-55] 30.1 [17-56]
Gender (Male/Female) 23/52 11/30 68/24
Positive rate of anti-SARS-CoV Ab 100.0%(75/75) 2.4%(1/41) 0.0%(0/92)BMC Infectious Diseases 2008, 8:27 http://www.biomedcentral.com/1471-2334/8/27
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238(G→A) among the three populations. However, the
CT genotype was less frequent in SARS group when com-
pared with individual controls at the -204 locus (X2 =
4.20, P = 0.04). Compared to TT genotype, the CT geno-
type at the -204 locus were found associated with a protec-
tive effect on SARS with OR(95%CI) of 0.95(0.90–0.99)
(Table 2).
According to the clinical history, symptoms of SARS
patients were classified into light and severe. Because of
the complicated clinical condition during SARS outbreak,
some patients' histories were incomplete and could not be
classified following the severity standard [22]. The severe
SARS referred to those with one or more of the following:
(1) dyspnea, more than 30 times per min respiratory fre-
quencies in still condition;(2) oxygenation index less than
300 mmHg; (3) shock or multiple organ dysfunction syn-
drome. Among all 75 patients, fifty-four were classified
into light and severe. And there were no association of
TNF-α polymorphisms and SARS severity (Table 3).
Glucocorticoid using in SARS with interstitial lung fibrosis 
or femoral head necrosis
Glucocorticoid using dosage, method and lasting period
were not associated with interstitial lung fibrosis or femo-
ral head necrosis in binary logistic analysis in SARS
patients (Table 4). And there was no difference of hor-
mone using dosage between the interstitial lung fibrosis
and non-interstitial lung fibrosis group(t = 0.72, P = 0.47)
and this trend was also observed in the femoral head
necrosis and non-femoral head necrosis group(t = 1.90, P
= 0.064) (Table 5).
TNF-α polymorphisms and interstitial lung fibrosis
Allele frequencies of TNF-α polymorphisms were listed in
Table 6 and there were no significant differences between
interstitial lung fibrosis and non-interstitial lung fibrosis
in SARS patients at promoter region of TNF-α gene.
TNF-α polymorphism and femoral head necrosis
Allele frequencies of TNF-α gene were compared in SARS
patients between femoral head necrosis and non-femoral
head necrosis (Table 7). The -1031 CT and CC genotypes
were more frequent in SARS patients with femoral head
necrosis(53.7% and 6.7%, respectively) than in non-fem-
oral head necrosis(20.0% and 0.0%, respectively). Com-
pared to TT genotype, CT and CC were found associated
with a risk effect on femoral head necrosis with
ORs(95%CI) of 5.33(1.39–20.45) and 5.67(2.74–11.71),
respectively. The adjusted OR of CT was 5.25(95%CI
1.18–23.46) and the combined (CT and CC) genotype
OR was 6.0 (95%CI 1.60–22.55). Also, the -863 AC gen-
otype accounted for 43.7% of femoral head necrosis
group but 10.8% of non-femoral head necrosis. Com-
pared to CC genotype, the AC genotype was manifested as
another risk effect associated with femoral head necrosis
with OR(95%CI) of 6.42(1.53–26.88) and the adjusted
OR was 8.40(95%CI 1.76–40.02) in cured SARS patients.
Discussion
Four years after SARS occurrence, many problems still
remained unknown to us. Till now, many researchers have
reported that susceptibility to infection SARS-CoV may
associate with HLA, MXA, OAS-1 and CLEC4M gene pol-
ymorphisms, yet the results are variable in different pop-
ulations [9-13]. These differences may be attributed to the
study population used in each report, also the complex
mechanism infection to SARS-CoV should be considered
as another factor of these differences. In order to explore
more host factor influence the occurrence of SARS-CoV
infection, we studied the polymorphisms of TNF-α gene
at the promoter region, which have been ascribed to pol-
ymorphisms within the regulatory regions or signal
sequences of cytokine genes [14]. Allele distributions at -
1031, -863, -857, -572, -238 and -163 were almost the
same among the SARS, the health care workers and indi-
vidual controls, but a higher A allele frequency in SARS
population when compared with the control at the -308
locus(X2  = 8.96, P  = 0.003). Though previous study
showed that TNF-α -308 AG genotype was associated with
the clearance of Hepatitis B virus and the infection of Heli-
cobacter pylori cagA subtype infection [24,25], our results
failed to show the role of this locus in SARS-CoV infection
and this conclusion agreed with that of Chong WP et al
[26]. We found that there was a weak protective effect of
CT genotype at -204 locus of TNF-α gene against SARS-
CoV infection. The -204 locus was a new discovered SNP
site of TNF-α promoter region and its role in infectious
diseases might need further study. At the same time, no
obvious association between the polymorphisms of TNF-
α promoter region with the severity of SARS was observed.
However, Lu reported that the -238G/A polymorphism of
TNF-α associated with the outcomes of hepatitis B virus
infection [27]. Thus, the roles of TNF-α gene in infectious
diseases should be further studied.
TNF-α, a key mediator of the inflammatory response, is
critical for host defense against a wide variety of patho-
genic microbes, but a higher concentration of this
cytokine may cause severe pathology. The capacity for
cytokine production in an individual has a major genetic
component, and striking differences existed among indi-
viduals in terms of their ability to produce cytokines. A
number of studies had shown that the TNF-α promoter
polymorphism has a significant effect on transcriptional
activity [6,7]. During the process of SARS-CoV infection,
there was a cytokine storm in patients including IL-1, IL-
2, IL-4, IL-6, IL-8, IL-10, IFN-γ, TNF-α and TGF-β1 [28].
The elevated levels of pro-inflammatory cytokines which
may cause immuno-mediated damage to lung and otherBMC Infectious Diseases 2008, 8:27 http://www.biomedcentral.com/1471-2334/8/27
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Table 2: TNF-α gene polymorphism in promoter region in cured SARS patients, health care workers and individual control
SNP site SARS (%) Health Care Workers (%) Individual Control (%) OR1 (95%CI) OR2 (95%CI)
-1031
Genotype
TT 45(63.4) 25(64.1) 61(67.8) - -
CT 23(32.4) 13(33.3) 27(30.0) 0.98(0.43–2.27) 1.12(0.59–2.27)
CC 3(4.2) 1(2.6) 2 (2.2) 1.67(0.17–16.88) 2.03(0.33–12.68)
Allele
T 79.6 80.8 74.5
C 20.4 19.2 25.5
-863
Genotype
CC 55(73.3) 29(72.5) 64(70.3) - -
AC 19(25.3) 11(27.5) 27(29.7) 0.91(0.38–2.17) 0.82(0.41–1.63)
AA 1(1.3) 0 0 0.98(0.94–1.07)& 2.16(1.78–2.63)&
Allele
C 86.0 86.3 85.2
A 14.0 13.7 14.8
-857
Genotype
CC 56(74.7) 31(77.5) 66(72.5) - -
CT 19(25.3) 8(20.0) 25(27.5) 1.32(0.52–3.35) 0.90(0.45–1.79)
TT 0 1(2.5) 0 1.03(0.97–1.1)$ -
Allele
C 131(87.3) 70(87.5) 157(86.3)
T 19(12.7) 10(12.5) 25(13.7)
-572
Genotype
AA 73(97.3) 40(97.6) 90(97.8) - -
AC 2(2.7) 1(2.4) 2(2.2) 1.10(0.10–12.46) 1.23(0.17–8.97)
Allele
A 98.7 98.8 98.9
C1 . 3 1 . 2 1 . 1
-308
Genotype
GG 67(89.3) 39(95.1) 88(95.7) - -
AG 7(9.1) 2(4.9) 4(4.3) 2.04(0.40–10.30) 2.30(0.65–8.18)
AA 1(1.3) 0 0 0.98(0.96–1.01)& 2.31(1.93–2.77)&
Allele
G 94.0 97.6 100.0
A6 . 0 2 . 4 0 . 0
-238
Genotype
GG 65(86.7) 39(95.1) 84(91.3) - -
AG 10(13.3) 2(4.9) 8(8.7) 3.00(0.63–14.41) 1.62(0.60–4.32)
Allele
G 93.3 97.6 95.7
A6 . 7 2 . 4 4 . 3
-204
Genotype
TT 75(100) 41(100.0) 87(94.6) - -
CT 0(0.0) 0 5(5.4) - 0.95(0.90–0.99)
$
Allele
T 100.0 100.0 97.3
C0 . 0 0 . 0 2 . 7
-163
Genotype
GG 74(98.7) 41(100.0) 87(94.6) - -
CG 1(1.3) 0 5 (5.4) 0.98(0.96–1.01)& 0.24(0.03–2.06)
Allele
G 99.3 100.0 97.3
C0 . 7 0 . 0 2 . 7
Note: OR1 was calculated by comparing SARS with HCW;
OR2 was calculated by comparing SARS with individual control;
&: Odds ratio replaced with SARS group; $: Odds ratio replaced with controlBMC Infectious Diseases 2008, 8:27 http://www.biomedcentral.com/1471-2334/8/27
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Table 3: TNF-α gene polymorphism and the progress of SARS
SNP site Severe SARS(%) Light SARS(%) OR* (95%CI) P
-1031
Genotype
TT 13(61.9) 22(73.3)
CT 7(33.3) 8(26.7) 1.48(0.44–5.04) 0.53
CC 1(4.8) 0(0.0) 2.69(1.75–4.14)
& 0.39
Allele
T7 8 . 68 6 . 7
C2 1 . 41 3 . 3
-863
Genotype
CC 19(79.2) 24(80.0)
AC 5(20.8) 6(20.0) 1.05(0.28–3.98) 0.60
Allele
C8 9 . 69 0 . 0
A1 0 . 41 0 . 0
-857
Genotype
CC 15(62.5) 24(80.0)
CT 9(37.5) 6(20.0) 2.40(0.71–8.11) 0.15
Allele
C 39(81.2) 54(90.0)
T 9(18.8) 6(10.0)
-572
Genotype
AA 24(100.0) 29(96.7)
AC 0(0.0) 1(3.3) 1.83(1.43–2.34) 1.00
Allele
A 100.0 98.3
C 0.0 1.7
-308
Genotype
GG 20(83.3) 27(90.0)
AG 4(16.7) 2(6.7) 2.70(0.45–16.22) 0.39
AA 0(0.0) 1(3.3) 1.74(1.36–2.23)
$ 1.00
Allele
G 100.0 93.3
A 0.0 6.7
-238
Genotype
GG 20(83.3) 27(90.0)
AG 4(16.7) 3(10.0) 1.80(0.36–8.96) 0.69
Allele
G 91.70 95.0
A 8.3 5.0
-204
Genotype
TT 24(100.0) 30(100.0)
Allele
T 100.0 100.0
-163
Genotype
GG 24(100.0) 30(100.0)
Allele
G 100.0 100.0
Note:*: OR was calculated using light SARS as control.
&: Odds ratio replaced with severity SARS group;
$: Odds ratio replaced with light SARSBMC Infectious Diseases 2008, 8:27 http://www.biomedcentral.com/1471-2334/8/27
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organs, resulting in acute lung injury and, subsequently,
multi-organ dysfunction [29]. So, TNF-α genetic variation
may potentially alter inflammation and fibrosis in the
lung. After discharging from hospital, interstitial lung
fibrosis was observed in cured SARS patients and the prev-
alence rate was 21%(42/200). TNF-α was one of the earli-
est cytokines implicated in the pathogenesis of lung
fibrosis disease and, together with IL-1, has been found to
over-express in regenerating type II pneumocytes in
human lung, thus enhancing fibroblast proliferation
[16].TNF-α genetic polymorphisms have been found sig-
nificantly associated with increased risk of developing
pulmonary fibrosis [17,18]. During the progress of idio-
pathic pulmonary fibrosis, activated epithelial cells are
thought to release potent fibrogenic molecules and
cytokines, such as TNF-α and TGF-β1, which in turn foster
the transformation of fibroblasts into myofibroblasts and
promote their production of extracellular matrix mole-
cules and a vicious cycle of injury and abnormal epithelial
healing sets the stage for progressive fibrosis and architec-
tural distortion of the lung parenchyma [7]. However, our
data failed to show that alleles at -1031(T→C), -
863(C→A), -857(C→T), -572(A→C), -308(G→A) and -
238(G→A) were related to interstitial lung fibrosis when
compared with non-interstitial lung fibrosis in SARS
patients. At the same time, -204 and -163 were homozy-
gote genotype of TT and GG respectively in SARS patients
and no relationship of genotype with interstitial lung
fibrosis could be calculated. This result implicated that
there maybe a different mechanism of interstitial lung
fibrosis of SARS compared with idiopathic pulmonary
fibrosis.
Femoral head necrosis, another sequela of discharged
SARS patients, prevailed with a rate of 22.07%(49/221) in
Tianjin [15]. However, the cause of this sequela was still
unknown and there were arguments about it. For exam-
ple, some author considered SARS-CoV as the cause of
femoral head necrosis, yet other authors disagree with this
view [20,21]. Previous studies showed that femoral head
necrosis may caused by hormone usage, our data was far
to agree with this conclusion. There was no obvious asso-
ciation between hormone using including hormone dos-
age, method and lasting period with femoral head
necrosis in binary logistic analysis in SARS patients. We
found that the -1031 CT and CC genotypes were more fre-
quent in SARS patients with femoral head necrosis(53.7%
and 6.7%, respectively) than in non-femoral head necro-
sis(20.0% and 0.0%, respectively). And CT and CC were
related with a risk effect on femoral head necrosis with
ORs (95%CI) of 5.33(1.39–20.45) and
5.67(2.74–11.71), respectively when compared to TT gen-
otype. The hormone using adjusted OR of CT was
5.25(95%CI 1.18–23.46) and the combined (CT and CC)
genotype OR was 6.0 (95%CI 1.60–22.55). Also, the -863
AC genotype accounted for 43.7% of femoral head necro-
sis group but 10.8% of non-femoral head necrosis. Com-
pared to CC genotype, the AC genotype was manifested as
another risk effect associated with femoral head necrosis
with OR(95%CI) of 6.42(1.53–26.88) and the adjusted
OR was 8.40(95%CI 1.76–40.02) in cured SARS patients.
Table 4: Binary logistic analysis of hormone using in SARS patients
Factors Interstitial lung fibrosis Femoral head necrosis
P OR 95.0% C.I. P OR 95.0% C.I.
Glucocorticoid 0.97 1.00 0.99 1.00 0.11 1.00 0.99 1.00
Time 0.78 0.97 0.81 1.18 0.96 1.00 0.84 1.18
Lash therapy 0.51 2.13 0.23 20.13 0.27 0.32 0.04 2.43
Constant 0.68 3.48 0.13 88.28
Table 5: Cumulative hormone usage (mg) in cured SARS patients classified according to interstitial lung fibrosis or femoral head 
necrosis
Mean ± SD Median P25 P75
Interstitial lung fibrosis&
Yes 5188.13 ± 2037.56 5140.00 3110.00 7288.75
No 4493.11 ± 2528.91 3895.00 2720.00 5975.00
Femoral head necrosis&&
Yes 5672.31 ± 2328.61 6090.00 3437.50 7872.50
No 4187.81 ± 2389.71 3807.50 2355.00 5707.50
&: hormone dosage between interstitial lung fibrosis and non-interstitial lung fibrosis, t = 0.72, P = 0.47;
&&: hormone dosage between femoral head necrosis and non-femoral head necrosis, t = 1.90, P = 0.064BMC Infectious Diseases 2008, 8:27 http://www.biomedcentral.com/1471-2334/8/27
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TNF-α can activate activity of osteoclasts and accelerate
absorption of the bone and cartilage and induce occur-
rence of oxygen free radicals an d lipid peroxidation,
which can induce ischemic necrosis of the femoral head
[30]. So, the ploymophism TNF-α gene may be directly or
indirectly attributed to the occurrence of femoral head
necrosis in SARS patients.
Conclusion
In conclusion, there may be no association of TNF-α pol-
ymorphisms in promoter region with SARS-Cov infection.
Also,  TNF-α  gene polymorphisms may no affect the
occurrence of interstitial lung fibrosis in cured SARS
patients. However, the polymorphisms may relate with
femoral head necrosis.
Table 6: TNF-α gene polymorphisms and the occurrence of interstitial lung fibrosis in SARS patients
SNP site Interstitial lung fibrosis(%) Non-interstitial lung fibrosis(%) OR* (95%C.I.) P
-1031
Genotype
TT 14(70) 12(57.1)
CT 6(30) 8(38.1) 0.64(0.17–2.38) 0.51
CC 0 1(4.8) 1.08(0.93–1.27)‡ 0.48
Allele
T 85.00 76.19
C 15.00 23.81
-863
Genotype
CC 17(77.3) 16(72.7)
AC 5(22.7) 6(27.3) 0.78(0.20–3.08) 0.73
Allele
C8 8 . 6 4 3 8
A 11.36 13.64
-857
Genotype
CC 15(68.8) 17(77.3)
CT 7(31.8) 5(22.7) 1.59(0.42–6.07) 0.50
Allele
C 84.09 88.64
T 15.91 11.36
-572
Genotype
AA 21(95.5) 22(100)
AC 1(4.5) 0 0.96(0.87–1.05)& 0.50
Allele
A 97.73 100.00
C 2.27 0.00
-308
Genotype
GG 21(95.5) 18(81.8)
AG 1(4.5) 4(18.2) 0.21(0.02–2.10) 0.17
Allele
G 97.73 90.9
A 2.27 9.1
-238
Genotype
GG 20(90.9) 18(81.8)
AG 2(9.1) 4(18.2) 0.45(0.07–2.76) 0.33
Allele
G 95.45 90.9
A 4.55 9.1
Note:*:OR was calculated using non-interstitial lung fibrosis as control.
&: Odds ratio replaced with interstitial lung fibrosis group;
‡: Odds ratio replaced with non-interstitial lung fibrosis groupBMC Infectious Diseases 2008, 8:27 http://www.biomedcentral.com/1471-2334/8/27
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